Meeting
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Hongli Li
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China
Hongli Li , Jingyu Deng , Shaohua Ge , Fenglin Zang , Le Zhang , Peng REN , Baogui Wang , Fuliang Cao , Ting Deng , Rui Liu , Tao Ning , Yuchong Yang , Ming Bai , Xia Wang , Zhi Ji , Jingjing Duan , Yong Liu , Dejun Zhou , Han Liang , Yi Ba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04354662
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4050)
DOI
10.1200/JCO.2021.39.15_suppl.4050
Abstract #
4050
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Ning Li
Poster
2019 ASCO Annual Meeting
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
First Author: Salah-Eddin Al-Batran
Poster
2021 ASCO Annual Meeting
MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
First Author: MARIA ALSINA
Poster
2017 ASCO Annual Meeting
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
First Author: Ralf Hofheinz